187 related articles for article (PubMed ID: 24122992)
1. Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells.
Carey JP; Knowell AE; Chinaranagari S; Chaudhary J
Anticancer Res; 2013 Oct; 33(10):4271-8. PubMed ID: 24122992
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.
Carey JP; Asirvatham AJ; Galm O; Ghogomu TA; Chaudhary J
BMC Cancer; 2009 Jun; 9():173. PubMed ID: 19500415
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of bHLH transcription factor E2A (TCF3) in prostate cancer promotes proliferation and confers resistance to doxorubicin induced apoptosis.
Patel D; Chaudhary J
Biochem Biophys Res Commun; 2012 May; 422(1):146-51. PubMed ID: 22564737
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor of differentiation 1 (Id1) and Id3 proteins play different roles in TGFβ effects on cell proliferation and migration in prostate cancer cells.
Strong N; Millena AC; Walker L; Chaudhary J; Khan SA
Prostate; 2013 May; 73(6):624-33. PubMed ID: 23060149
[TBL] [Abstract][Full Text] [Related]
5. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells.
Asirvatham AJ; Schmidt MA; Chaudhary J
Prostate; 2006 Jun; 66(9):921-35. PubMed ID: 16541417
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor of differentiation 4 (ID4) acts as an inhibitor of ID-1, -2 and -3 and promotes basic helix loop helix (bHLH) E47 DNA binding and transcriptional activity.
Sharma P; Chinaranagari S; Chaudhary J
Biochimie; 2015 May; 112():139-50. PubMed ID: 25778840
[TBL] [Abstract][Full Text] [Related]
7. ID1-, ID2-, and ID3-regulated gene expression in E2A positive or negative prostate cancer cells.
Asirvatham AJ; Carey JP; Chaudhary J
Prostate; 2007 Sep; 67(13):1411-20. PubMed ID: 17639499
[TBL] [Abstract][Full Text] [Related]
8. Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B.
Sharma P; Patel D; Chaudhary J
Cancer Med; 2012 Oct; 1(2):187-97. PubMed ID: 23342268
[TBL] [Abstract][Full Text] [Related]
9. ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells.
Komaragiri SK; Bostanthirige DH; Morton DJ; Patel D; Joshi J; Upadhyay S; Chaudhary J
Biochem Biophys Res Commun; 2016 Sep; 478(1):60-66. PubMed ID: 27462022
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer.
Sharma P; Chinaranagari S; Patel D; Carey J; Chaudhary J
Cancer Med; 2012 Oct; 1(2):176-86. PubMed ID: 23342267
[TBL] [Abstract][Full Text] [Related]
11. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.
Sharma P; Knowell AE; Chinaranagari S; Komaragiri S; Nagappan P; Patel D; Havrda MC; Chaudhary J
Mol Cancer; 2013 Jun; 12():67. PubMed ID: 23786676
[TBL] [Abstract][Full Text] [Related]
12. Hormonal regulation and differential actions of the helix-loop-helix transcriptional inhibitors of differentiation (Id1, Id2, Id3, and Id4) in Sertoli cells.
Chaudhary J; Johnson J; Kim G; Skinner MK
Endocrinology; 2001 May; 142(5):1727-36. PubMed ID: 11316735
[TBL] [Abstract][Full Text] [Related]
13. Id4 dependent acetylation restores mutant-p53 transcriptional activity.
Knowell AE; Patel D; Morton DJ; Sharma P; Glymph S; Chaudhary J
Mol Cancer; 2013 Dec; 12():161. PubMed ID: 24330748
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer.
Patel D; Knowell AE; Korang-Yeboah M; Sharma P; Joshi J; Glymph S; Chinaranagari S; Nagappan P; Palaniappan R; Bowen NJ; Chaudhary J
Mol Endocrinol; 2014 Aug; 28(8):1239-53. PubMed ID: 24921661
[TBL] [Abstract][Full Text] [Related]
15. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.
Fontemaggi G; Dell'Orso S; Trisciuoglio D; Shay T; Melucci E; Fazi F; Terrenato I; Mottolese M; Muti P; Domany E; Del Bufalo D; Strano S; Blandino G
Nat Struct Mol Biol; 2009 Oct; 16(10):1086-93. PubMed ID: 19783986
[TBL] [Abstract][Full Text] [Related]
16. E2F-1 is a critical modulator of cellular senescence in human cancer.
Park C; Lee I; Kang WK
Int J Mol Med; 2006 May; 17(5):715-20. PubMed ID: 16596252
[TBL] [Abstract][Full Text] [Related]
17. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
Laine A; Sihto H; Come C; Rosenfeldt MT; Zwolinska A; Niemelä M; Khanna A; Chan EK; Kähäri VM; Kellokumpu-Lehtinen PL; Sansom OJ; Evan GI; Junttila MR; Ryan KM; Marine JC; Joensuu H; Westermarck J
Cancer Discov; 2013 Feb; 3(2):182-97. PubMed ID: 23306062
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
19. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
